{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:14:51Z","timestamp":1791616491664,"version":"4.3.4"},"reference-count":119,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jaip.2019.02.002","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T05:14:19Z","timestamp":1554441259000},"page":"1097-1106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"title":["Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management"],"prefix":"10.1016","volume":"7","author":[{"given":"Mariana","family":"Castells","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2019.02.002_bib1","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaci.2018.06.004","article-title":"Mast cell activation syndrome: importance of consensus criteria and call for research","volume":"142","author":"Valent","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.iac.2014.02.003","article-title":"Diagnostic criteria and classification of mastocytosis in 2014","volume":"34","author":"Akin","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2019.02.002_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11882-012-0326-8","article-title":"Immunology and clinical manifestations of non-clonal mast cell activation syndrome","volume":"13","author":"Cardet","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2019.02.002_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0145-2126(01)00046-7","article-title":"Mastocytosis: molecular mechanisms and clinical disease heterogeneity","volume":"25","author":"Metcalfe","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2019.02.002_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib6","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2019.02.002_bib7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11588890-000000000-00000","article-title":"Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations","volume":"12","author":"Castells","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2019.02.002_bib8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jaip.2019.02.002_bib9","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/j.1398-9995.2009.02108.x","article-title":"How much specific is the association between hymenoptera venom allergy and mastocytosis?","volume":"64","author":"Bonadonna","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.02.002_bib10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","article-title":"Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis","volume":"137","author":"Alvarez-Twose","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib11","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1200\/JCO.2011.38.9973","article-title":"Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis","volume":"30","author":"Alvarez-Twose","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2019.02.002_bib12","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2019.02.002_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2011.04.037","article-title":"Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations","volume":"128","author":"Hamilton","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib14","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib15","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.jaci.2013.11.039","article-title":"Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities","volume":"133","author":"Lyons","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib16","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1073\/pnas.83.12.4464","article-title":"Two types of human mast cells that have distinct neutral protease compositions","volume":"83","author":"Irani","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jaip.2019.02.002_bib17","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0344-0338(11)80086-5","article-title":"Heterogeneity of mast cells at multiple body sites. Fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content","volume":"189","author":"Weidner","year":"1993","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.jaip.2019.02.002_bib18","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/ni.3445","article-title":"Expression profiling of constitutive mast cells reveals a unique identity within the immune system","volume":"17","author":"Dwyer","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000048188","article-title":"Mastocytosis: mediator-related signs and symptoms","volume":"127","author":"Castells","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib20","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.10.020","article-title":"Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes","volume":"125","author":"Teodosio","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1113\/jphysiol.1910.sp001406","article-title":"The physiological action of beta-iminazolylethylamine","volume":"41","author":"Dale","year":"1910","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.jaip.2019.02.002_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/164_2017_18","article-title":"Histamine release from mast cells and basophils","volume":"241","author":"Borriello","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jaip.2019.02.002_bib23","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/MOG.0000000000000392","article-title":"Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion","volume":"33","author":"Schubert","year":"2017","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jaip.2019.02.002_bib24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0002-9343(89)80398-5","article-title":"Analysis of plasma histamine levels in patients with mast cell disorders","volume":"87","author":"Friedman","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.jaip.2019.02.002_bib25","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1056\/NEJM198312293092603","article-title":"Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites","volume":"309","author":"Keyzer","year":"1983","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.02.002_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01968810","article-title":"Aspects of histamine metabolism","volume":"22","author":"Green","year":"1987","journal-title":"Agents Actions"},{"key":"10.1016\/j.jaip.2019.02.002_bib27","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/ajcn\/85.5.1185","article-title":"Histamine and histamine intolerance","volume":"85","author":"Maintz","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jaip.2019.02.002_bib28","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/all.12668","article-title":"Urinary 11beta-PGF2alpha and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders","volume":"70","author":"Divekar","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.02.002_bib29","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaip.2014.06.011","article-title":"Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11beta-prostaglandin2alpha","volume":"2","author":"Ravi","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.02.002_bib30","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.4049\/jimmunol.138.7.2184","article-title":"Evaluation of human peripheral blood leukocytes for mast cell tryptase","volume":"138","author":"Castells","year":"1987","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib31","doi-asserted-by":"crossref","first-page":"7372","DOI":"10.1016\/S0021-9258(17)38401-6","article-title":"Regulation of tryptase from human lung mast cells by heparin. Stabilization of the active tetramer","volume":"261","author":"Schwartz","year":"1986","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaip.2019.02.002_bib32","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1172\/JCI114051","article-title":"Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis","volume":"83","author":"Schwartz","year":"1989","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2019.02.002_bib33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2006.05.010","article-title":"Diagnostic value of tryptase in anaphylaxis and mastocytosis","volume":"26","author":"Schwartz","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2019.02.002_bib35","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2500\/aap.2014.35.3769","article-title":"Serum basal tryptase levels in healthy children: correlation between age and gender","volume":"35","author":"Sahiner","year":"2014","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2019.02.002_bib36","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1399-3038.2011.01166.x","article-title":"Total serum tryptase levels are higher in young infants","volume":"22","author":"Belhocine","year":"2011","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ajd.12146","article-title":"Disease spectrum in patients with elevated serum tryptase levels","volume":"56","author":"Aberer","year":"2015","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaip.2019.02.002_bib38","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.aller.2014.05.002","article-title":"Clinical characteristics and risk profile of patients with elevated baseline serum tryptase","volume":"42","author":"Fellinger","year":"2014","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.jaip.2019.02.002_bib39","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jaci.2014.06.007","article-title":"Familial hypertryptasemia with associated mast cell activation syndrome","volume":"134","author":"Sabato","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib40","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaip.2019.02.002_bib41","doi-asserted-by":"crossref","first-page":"14621","DOI":"10.1016\/S0021-9258(17)38613-1","article-title":"Hepatic transformation of prostaglandin D2 to a new prostanoid, 9 alpha,11 beta-prostaglandin F2, that inhibits platelet aggregation and constricts blood vessels","volume":"260","author":"Pugliese","year":"1985","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaip.2019.02.002_bib42","first-page":"1","article-title":"Systemic mastocytosis: management of an unusual case with histamine (H1 and H2) antagonists and cyclooxygenase inhibition","volume":"10","author":"Crawhall","year":"1987","journal-title":"Clin Invest Med"},{"key":"10.1016\/j.jaip.2019.02.002_bib43","first-page":"18","article-title":"The flush syndrome: an expression of systemic mastocytosis with increased prostaglandin D2 production","volume":"26","author":"Kootte","year":"1983","journal-title":"Neth J Med"},{"issue":"Pt 1","key":"10.1016\/j.jaip.2019.02.002_bib44","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/01.HYP.6.2.285","article-title":"Recurrent syncope due to systemic mastocytosis","volume":"6","author":"Roberts","year":"1984","journal-title":"Hypertension"},{"key":"10.1016\/j.jaip.2019.02.002_bib45","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(89)91516-X","article-title":"Aspirin and systemic mastocytosis","volume":"2","author":"Lorcerie","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.02.002_bib46","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.prostaglandins.2009.01.001","article-title":"Survey of aspirin administration in systemic mastocytosis","volume":"88","author":"Butterfield","year":"2009","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.jaip.2019.02.002_bib47","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000144042","article-title":"Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production","volume":"147","author":"Butterfield","year":"2008","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib48","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4065\/70.5.481","article-title":"Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization","volume":"70","author":"Butterfield","year":"1995","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaip.2019.02.002_bib49","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1398-9995.1997.tb00966.x","article-title":"Measurements of leukotrienes in the urine: strategies and applications","volume":"52","author":"Kumlin","year":"1997","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.02.002_bib50","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2222.1995.tb01079.x","article-title":"Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans","volume":"25","author":"Kumlin","year":"1995","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2019.02.002_bib51","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.clinbiochem.2016.02.007","article-title":"Analytical and clinical validation of an LC-MS\/MS method for urine leukotriene E4: a marker of systemic mastocytosis","volume":"49","author":"Lueke","year":"2016","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jaip.2019.02.002_bib52","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1734-1140(10)70306-6","article-title":"Transcellular biosynthesis of eicosanoids","volume":"62","author":"Sala","year":"2010","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.jaip.2019.02.002_bib53","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000237133","article-title":"Cysteinyl leukotriene production in anaphylactic reactions","volume":"108","author":"Denzlinger","year":"1995","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib54","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.prostaglandins.2010.03.003","article-title":"Increased leukotriene E4 excretion in systemic mastocytosis","volume":"92","author":"Butterfield","year":"2010","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.jaip.2019.02.002_bib55","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000063858","article-title":"Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients","volume":"128","author":"Theoharides","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib56","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clim.2005.01.011","article-title":"IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis","volume":"115","author":"Brockow","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib57","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/leu.2015.176","article-title":"Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression","volume":"30","author":"Mayado","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2019.02.002_bib58","doi-asserted-by":"crossref","first-page":"e112989","DOI":"10.1371\/journal.pone.0112989","article-title":"Differential effects of the Toll-like receptor 2 agonists, PGN and Pam3CSK4 on anti-IgE induced human mast cell activation","volume":"9","author":"Yu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2019.02.002_bib59","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejphar.2012.12.003","article-title":"Inhibitory effects of benzodiazepines on the adenosine A(2B) receptor mediated secretion of interleukin-8 in human mast cells","volume":"700","author":"Hoffmann","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jaip.2019.02.002_bib60","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1128\/IAI.00270-08","article-title":"Human mast cell activation by Staphylococcus aureus: interleukin-8 and tumor necrosis factor alpha release and the role of Toll-like receptor 2 and CD48 molecules","volume":"76","author":"Rocha-de-Souza","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaip.2019.02.002_bib61","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.atherosclerosis.2010.11.024","article-title":"OxLDL-IgG immune complexes induce expression and secretion of proatherogenic cytokines by cultured human mast cells","volume":"214","author":"Lappalainen","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jaip.2019.02.002_bib62","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10719-016-9749-0","article-title":"Mast cell glycosaminoglycans","volume":"34","author":"Mulloy","year":"2017","journal-title":"Glycoconj J"},{"key":"10.1016\/j.jaip.2019.02.002_bib63","doi-asserted-by":"crossref","first-page":"e0124912","DOI":"10.1371\/journal.pone.0124912","article-title":"Determination of plasma heparin level improves identification of systemic mast cell activation disease","volume":"10","author":"Vysniauskaite","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2019.02.002_bib64","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/1076029607309173","article-title":"Fatal bleeding due to a heparin-like anticoagulant in a 37-year-old woman suffering from systemic mastocytosis","volume":"14","author":"Sucker","year":"2008","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jaip.2019.02.002_bib65","first-page":"404","article-title":"Role of heparin and heparinlike molecules in thrombosis and atherosclerosis","volume":"44","author":"Rosenberg","year":"1985","journal-title":"Fed Proc"},{"key":"10.1016\/j.jaip.2019.02.002_bib66","doi-asserted-by":"crossref","first-page":"9416","DOI":"10.1016\/S0021-9258(17)36896-5","article-title":"Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase)","volume":"269","author":"Stack","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaip.2019.02.002_bib67","first-page":"LB573","article-title":"Glycosaminoglycans inhibit substance P and IL-33-stimulated IL-8 and TNF release from human-cultured mast cells","volume":"31","author":"Rae Gross","year":"2017","journal-title":"FASEB J"},{"key":"10.1016\/j.jaip.2019.02.002_bib68","doi-asserted-by":"crossref","first-page":"30059","DOI":"10.1038\/srep30059","article-title":"Serotonin biosynthesis as a predictive marker of serotonin pharmacodynamics and disease-induced dysregulation","volume":"6","author":"Welford","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaip.2019.02.002_bib69","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2008.02047.x","article-title":"Clinical correlates of blood serotonin levels in patients with mastocytosis","volume":"38","author":"Kushnir-Sukhov","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jaip.2019.02.002_bib70","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jaip.2017.08.022","article-title":"Chromogranin A is not a biomarker of mastocytosis","volume":"6","author":"Hanjra","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.02.002_bib71","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1398-9995.2011.02550.x","article-title":"Neuropeptide blood levels correlate with mast cell load in patients with mastocytosis","volume":"66","author":"Maintz","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.02.002_bib72","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/en.2003-0805","article-title":"Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells","volume":"145","author":"Kempuraj","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.jaip.2019.02.002_bib73","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jaci.2014.05.023","article-title":"High serum corticotropin-releasing hormone (CRH) and bone marrow mast cell CRH receptor expression in a mastocytosis patient","volume":"134","author":"Theoharides","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib74","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jaci.2010.01.056","article-title":"Activation of human mast cells through the platelet-activating factor receptor","volume":"125","author":"Kajiwara","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib75","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1365-2567.2000.00972.x","article-title":"Demonstration that platelet-activating factor is capable of activating mast cells and inducing a chemotactic response","volume":"99","author":"Nilsson","year":"2000","journal-title":"Immunology"},{"key":"10.1016\/j.jaip.2019.02.002_bib76","first-page":"391","article-title":"Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis","volume":"77","author":"Macpherson","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib77","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0140-6736(88)90055-4","article-title":"Treatment of adult systemic mastocytosis with a PAF-acether antagonist BN52063","volume":"2","author":"Guinot","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.02.002_bib78","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2567.2008.02916.x","article-title":"Signalling mechanisms regulating the activation of human eosinophils by mast-cell-derived chymase: implications for mast cell-eosinophil interaction in allergic inflammation","volume":"126","author":"Wong","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jaip.2019.02.002_bib79","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/cvr\/cvr147","article-title":"Contributions of ACE and mast cell chymase to endogenous angiotensin II generation and leucocyte recruitment in\u00a0vivo","volume":"92","author":"Company","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jaip.2019.02.002_bib80","first-page":"847","article-title":"Mast-cell phenotype in indolent forms of mastocytosis. Ultrastructural features, fluorescence detection of avidin binding, and immunofluorescent determination of chymase, tryptase, and carboxypeptidase","volume":"140","author":"Weidner","year":"1992","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaip.2019.02.002_bib81","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.4049\/jimmunol.163.5.2799","article-title":"Stem cell factor is localized in, released from, and cleaved by human mast cells","volume":"163","author":"de Paulis","year":"1999","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib82","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/1471-2164-12-196","article-title":"Identification of novel target genes of nerve growth factor (NGF) in human mastocytoma cell line (HMC-1 (V560G c-Kit)) by transcriptome analysis","volume":"12","author":"Dutta","year":"2011","journal-title":"BMC Genomics"},{"key":"10.1016\/j.jaip.2019.02.002_bib83","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1182\/blood-2012-12-469882","article-title":"Increased circulating levels of neurotrophins and elevated expression of their high-affinity receptors on skin and gut mast cells in mastocytosis","volume":"122","author":"Peng","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2019.02.002_bib84","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2019.02.002_bib85","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.iac.2018.04.006","article-title":"Patient perceptions in mast cell disorders","volume":"38","author":"Jennings","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2019.02.002_bib86","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jaci.2013.06.020","article-title":"Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM","volume":"133","author":"Alvarez-Twose","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib87","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0091-6749(90)90067-E","article-title":"Cromolyn sodium in the management of systemic mastocytosis","volume":"85","author":"Horan","year":"1990","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib88","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1067\/mai.2000.104571","article-title":"Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema","volume":"105","author":"Wong","year":"2000","journal-title":"J\u00a0Allergy Clin Immunology"},{"key":"10.1016\/j.jaip.2019.02.002_bib89","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00005792-198811000-00001","article-title":"Systemic mast cell disease. Analysis of 58 cases and literature review","volume":"67","author":"Travis","year":"1988","journal-title":"Medicine"},{"key":"10.1016\/j.jaip.2019.02.002_bib90","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jaci.2014.05.003","article-title":"Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis","volume":"134","author":"van der Veer","year":"2014","journal-title":"J\u00a0Allergy Clin Immunology"},{"key":"10.1016\/j.jaip.2019.02.002_bib91","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000091172","article-title":"Elevated tryptase levels are associated with greater bone density in a cohort of patients with SM","volume":"139","author":"Kushnir-Sukhov","year":"2006","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib92","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s00198-016-3539-1","article-title":"Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis","volume":"27","author":"Rossini","year":"2016","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.jaip.2019.02.002_bib93","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2169\/internalmedicine.48.2294","article-title":"Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha","volume":"48","author":"Yoshida","year":"2009","journal-title":"Intern Med"},{"key":"10.1016\/j.jaip.2019.02.002_bib94","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/ajh.24382","article-title":"Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients","volume":"91","author":"Pieri","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2019.02.002_bib95","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.leukres.2004.05.003","article-title":"Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long-term follow-up of a case","volume":"29","author":"Butterfield","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2019.02.002_bib96","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","article-title":"Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature","volume":"28","author":"Hauswirth","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2019.02.002_bib97","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.amjmed.2011.02.038","article-title":"Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis","volume":"124","author":"Laroche","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.jaip.2019.02.002_bib98","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/ced.13408","article-title":"Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair\u00ae)","volume":"43","author":"Hughes","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2019.02.002_bib99","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaip.2014.03.009","article-title":"Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report","volume":"2","author":"Sokol","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.02.002_bib100","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/all.13237","article-title":"Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations","volume":"73","author":"Broesby-Olsen","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.02.002_bib101","doi-asserted-by":"crossref","first-page":"903541","DOI":"10.1155\/2015\/903541","article-title":"Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab","volume":"2015","author":"Lieberoth","year":"2015","journal-title":"Case Rep Med"},{"key":"10.1016\/j.jaip.2019.02.002_bib102","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jaip.2015.03.015","article-title":"Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both?","volume":"3","author":"Castells","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.02.002_bib103","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jaip.2013.07.004","article-title":"Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome","volume":"1","author":"da Silva","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.02.002_bib104","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.anai.2018.03.027","article-title":"Mast cell disorders: protean manifestations and treatment responses","volume":"121","author":"Chen","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib105","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.anai.2014.05.001","article-title":"Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome","volume":"113","author":"Jagdis","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2019.02.002_bib106","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast-cell disease with cladribine","volume":"344","author":"Tefferi","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.02.002_bib107","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2019.02.002_bib108","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2019.02.002_bib109","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1182\/blood-2015-06-649525","article-title":"Cladribine for mastocytosis: benefits and risks","volume":"126","author":"Akin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2019.02.002_bib110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcv.2016.12.005","article-title":"Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine","volume":"88","author":"Alstadhaug","year":"2017","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.jaip.2019.02.002_bib111","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2019.02.002_bib112","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.jaip.2019.02.002_bib113","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast-cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.02.002_bib114","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.leukres.2003.09.001","article-title":"Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis","volume":"28","author":"Musto","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2019.02.002_bib115","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1182\/blood.V116.21.316.316","article-title":"KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial","volume":"116","author":"Gotlib","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2019.02.002_bib116","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers","volume":"130","author":"Jawhar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2019.02.002_bib117","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaip.2019.02.002_bib118","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1600-0609.2008.01048.x","article-title":"Dasatinib therapy for systemic mastocytosis: four cases","volume":"80","author":"Purtill","year":"2008","journal-title":"Eur J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.jaip.2019.02.002_bib119","first-page":"2","article-title":"Clinical activity in a phase 1 study of Blu-285, a potent, highly-selective inhibitor of KIT D186V in advanced systemic mastocytosis (AdvSM)","volume":"130","author":"DeAngelo","year":"2017","journal-title":"Blood"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321981930159X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321981930159X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:18:57Z","timestamp":1761974337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221321981930159X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":119,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S221321981930159X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2019.02.002","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2019.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}